口服补充剂可以改善肝脏脑病变. 一个随机对照试验的结果
Lancet (London, England)
|September 1, 1984
概括
短期补充剂通过纠正缺乏症,改善了肝硬化患者的肝脑病变. 这种干预可以使血清水平正常化,并增强认知功能,这表明在治疗这种疾病方面具有潜在的治疗作用.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 营养科学 营养科学
- 神经学 神经学
背景情况:
- 慢性肝脑病是肝硬化的一个严重并发症.
- 缺乏症在肝硬化患者中很常见,可能导致脑病变.
- 氨转化为尿素对于肝脏疾病中排毒至关重要.
研究的目的:
- 为了研究口服补充剂在患有肝硬化慢性肝脑病变的患者中的疗效.
- 评估酸对血清水平和认知功能的影响.
主要方法:
- 一项双盲随机试验与22名肝硬化患者进行.
- 患者接受了口服乙酸盐 (600毫克/天7天) 或安慰剂.
- 肝发性脑病变被评估使用轨迹测试;测量血清和血液尿素.
主要成果:
- 在补充的组中,血清水平在第8天正常化.
- 与安慰剂相比,在补充的组中,肝脏脑病的改善显示出改善.
- 在接受的患者中观察到血液尿素的显著增加.
结论:
- 短期口服补充剂似乎可以改善肝硬化患者的肝脑病变.
- 该机制可能涉及纠正缺乏,从而增强氨转化为尿素的机制.
- 需要进一步的研究来确定补充剂的长期疗效和最佳持续时间.
更多相关视频
04:54Assessing Mineral Availability in Fish Feeds using Complementary Methods Demonstrated with the Example of Zinc in Atlantic Salmon
Published on: October 29, 2021
08:36The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
Published on: April 19, 2024
相关概念视频
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...